-
Je něco špatně v tomto záznamu ?
Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC
T. Hložek, L. Uttl, L. Kadeřábek, M. Balíková, E. Lhotková, RR. Horsley, P. Nováková, K. Šíchová, K. Štefková, F. Tylš, M. Kuchař, T. Páleníček,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
- MeSH
- akustická stimulace MeSH
- analýza rozptylu MeSH
- aplikace inhalační MeSH
- aplikace orální MeSH
- časové faktory MeSH
- fixní kombinace léků MeSH
- injekce subkutánní MeSH
- kanabidiol aplikace a dávkování farmakokinetika MeSH
- krysa rodu rattus MeSH
- mozek účinky léků metabolismus MeSH
- pátrací chování účinky léků MeSH
- plynová chromatografie s hmotnostně spektrometrickou detekcí MeSH
- potkani Wistar MeSH
- prepulsní inhibice účinky léků MeSH
- tetrahydrokanabinol aplikace a dávkování farmakokinetika MeSH
- tkáňová distribuce účinky léků MeSH
- způsoby aplikace léků MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Metabolic and behavioural effects of, and interactions between Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are influenced by dose and administration route. Therefore we investigated, in Wistar rats, effects of pulmonary, oral and subcutaneous (sc.) THC, CBD and THC+CBD. Concentrations of THC, its metabolites 11-OH-THC and THC-COOH, and CBD in serum and brain were determined over 24h, locomotor activity (open field) and sensorimotor gating (prepulse inhibition, PPI) were also evaluated. In line with recent knowledge we expected metabolic and behavioural interactions between THC and CBD. While cannabinoid serum and brain levels rapidly peaked and diminished after pulmonary administration, sc. and oral administration produced long-lasting levels of cannabinoids with oral reaching the highest brain levels. Except pulmonary administration, CBD inhibited THC metabolism resulting in higher serum/brain levels of THC. Importantly, following sc. and oral CBD alone treatments, THC was also detected in serum and brain. S.c. cannabinoids caused hypolocomotion, oral treatments containing THC almost complete immobility. In contrast, oral CBD produced mild hyperlocomotion. CBD disrupted, and THC tended to disrupt PPI, however their combination did not. In conclusion, oral administration yielded the most pronounced behavioural effects which corresponded to the highest brain levels of cannabinoids. Even though CBD potently inhibited THC metabolism after oral and sc. administration, unexpectedly it had minimal impact on THC-induced behaviour. Of central importance was the novel finding that THC can be detected in serum and brain after administration of CBD alone which, if confirmed in humans and given the increasing medical use of CBD-only products, might have important legal and forensic ramifications.
3rd Faculty of Medicine Charles University Ruská 87 100 00 Prague 10 Czech Republic
National Institute of Mental Health Topolová 748 250 67 Klecany Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18033572
- 003
- CZ-PrNML
- 005
- 20181024152358.0
- 007
- ta
- 008
- 181008s2017 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.euroneuro.2017.10.037 $2 doi
- 035 __
- $a (PubMed)29129557
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Hložek, Tomáš $u Institute of Forensic Medicine and Toxicology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 121 08 Prague 2, Czech Republic; Department of Analytical Chemistry, Faculty of Science, Charles University, Albertov 6, 128 43 Prague 2, Czech Republic.
- 245 10
- $a Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC / $c T. Hložek, L. Uttl, L. Kadeřábek, M. Balíková, E. Lhotková, RR. Horsley, P. Nováková, K. Šíchová, K. Štefková, F. Tylš, M. Kuchař, T. Páleníček,
- 520 9_
- $a Metabolic and behavioural effects of, and interactions between Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are influenced by dose and administration route. Therefore we investigated, in Wistar rats, effects of pulmonary, oral and subcutaneous (sc.) THC, CBD and THC+CBD. Concentrations of THC, its metabolites 11-OH-THC and THC-COOH, and CBD in serum and brain were determined over 24h, locomotor activity (open field) and sensorimotor gating (prepulse inhibition, PPI) were also evaluated. In line with recent knowledge we expected metabolic and behavioural interactions between THC and CBD. While cannabinoid serum and brain levels rapidly peaked and diminished after pulmonary administration, sc. and oral administration produced long-lasting levels of cannabinoids with oral reaching the highest brain levels. Except pulmonary administration, CBD inhibited THC metabolism resulting in higher serum/brain levels of THC. Importantly, following sc. and oral CBD alone treatments, THC was also detected in serum and brain. S.c. cannabinoids caused hypolocomotion, oral treatments containing THC almost complete immobility. In contrast, oral CBD produced mild hyperlocomotion. CBD disrupted, and THC tended to disrupt PPI, however their combination did not. In conclusion, oral administration yielded the most pronounced behavioural effects which corresponded to the highest brain levels of cannabinoids. Even though CBD potently inhibited THC metabolism after oral and sc. administration, unexpectedly it had minimal impact on THC-induced behaviour. Of central importance was the novel finding that THC can be detected in serum and brain after administration of CBD alone which, if confirmed in humans and given the increasing medical use of CBD-only products, might have important legal and forensic ramifications.
- 650 _2
- $a akustická stimulace $7 D000161
- 650 _2
- $a aplikace inhalační $7 D000280
- 650 _2
- $a aplikace orální $7 D000284
- 650 _2
- $a analýza rozptylu $7 D000704
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a mozek $x účinky léků $x metabolismus $7 D001921
- 650 _2
- $a kanabidiol $x aplikace a dávkování $x farmakokinetika $7 D002185
- 650 _2
- $a tetrahydrokanabinol $x aplikace a dávkování $x farmakokinetika $7 D013759
- 650 _2
- $a způsoby aplikace léků $7 D004333
- 650 _2
- $a fixní kombinace léků $7 D004338
- 650 _2
- $a pátrací chování $x účinky léků $7 D005106
- 650 _2
- $a plynová chromatografie s hmotnostně spektrometrickou detekcí $7 D008401
- 650 _2
- $a injekce subkutánní $7 D007279
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a prepulsní inhibice $x účinky léků $7 D065808
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a tkáňová distribuce $x účinky léků $7 D014018
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Uttl, Libor $u National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic; Department of Physiology, Faculty of Science, Charles University, Albertov 6, 128 43 Prague 2, Czech Republic.
- 700 1_
- $a Kadeřábek, Lukáš $u National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic.
- 700 1_
- $a Balíková, Marie $u Institute of Forensic Medicine and Toxicology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 121 08 Prague 2, Czech Republic.
- 700 1_
- $a Lhotková, Eva $u National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic.
- 700 1_
- $a Horsley, Rachel R $u National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic.
- 700 1_
- $a Nováková, Pavlína $u National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic.
- 700 1_
- $a Šíchová, Klára $u National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic.
- 700 1_
- $a Štefková, Kristýna $u National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic.
- 700 1_
- $a Tylš, Filip $u National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic.
- 700 1_
- $a Kuchař, Martin $u National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic; 3rd Faculty of Medicine, Charles University, Ruská 87, 100 00 Prague 10, Czech Republic.
- 700 1_
- $a Páleníček, Tomáš $u National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic; Faculty of Food and Biochemical Technology, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague 6, Czech Republic. Electronic address: tomas.palenicek@nudz.cz.
- 773 0_
- $w MED00001656 $t European neuropsychopharmacology the journal of the European College of Neuropsychopharmacology $x 1873-7862 $g Roč. 27, č. 12 (2017), s. 1223-1237
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29129557 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20181008 $b ABA008
- 991 __
- $a 20181024152907 $b ABA008
- 999 __
- $a ok $b bmc $g 1339506 $s 1030566
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 27 $c 12 $d 1223-1237 $e 20171110 $i 1873-7862 $m European neuropsychopharmacology $n Eur Neuropsychopharmacol $x MED00001656
- LZP __
- $a Pubmed-20181008
